Byondis B.V., an independent clinical stage biopharmaceutical company creating innovative targeted medicines for patients ...

We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider ...

Muzastotug Phase 2 dose expansion in MSS CRC with a 20 mg/kg loading dose regimen shows 33% overall response rate with four confirmed partial ...

The Breez 2 mL micro-bioreactor platform is a fully automated, functionally closed, and continuous perfusion cell culture ...

Celonic Group, a Swiss-Based Quality CDMO, is integrating Merck’s Breez micro-bioreactor platform into its process ...

AstraZeneca has tapped Korea's Alteogen to develop subcutaneous cancer drugs. Taiho Pharmaceutical is paying $400 million to ...

Muzastotug Phase 2 dose expansion in MSS CRC with a 20 mg/kg loading dose regimen shows 33% overall response rate with four confirmed partial responses SAFEbody technology utilized to create masked ...

A TROP2-directed antibody-drug conjugate, DB-1305/BNT325, demonstrated durable activity in patients with previously treated ovarian cancer in a first-in-human trial. These results were presented at ...

The deal with startup Dren Bio hands Sanofi a so-called myeloid cell engager that would compete with an array of programs ...

Merck has antibody data expected in mid-2025, and I look forward to seeing what we learn at AD/PD in April, AAIC in July, and CTAD in the fall. Okay. I promised I would keep it short. I just want ...

when Merck entered into an agreement with Daiichi Sankyo (OTCPK:DSKYF) to develop several antibody-drug conjugates. For comparison, and using Seeking Alpha data, Merck's non-GAAP EPS is expected ...

AstraZeneca has signed two deals worth $1.35 billion with Alteogen to develop subcutaneous versions of the British pharma’s ...